{"transactions":[{"id":731663,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-18T21:43:00.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan)."}],"balance_after":50000,"derivative":{"exercise_price":9.42,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001193125-26-276168","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1617239/000119312526276168/ownership.xml","form_type":"4"}},{"id":743225,"issuer":{"id":5418,"kind":"organization","name":"Cabaletta Bio, Inc."},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-10T23:04:14.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of the Corporation's stockholders."}],"balance_after":22000,"derivative":{"exercise_price":3.22,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001193125-26-266239","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759138/000119312526266239/ownership.xml","form_type":"4"}},{"id":934308,"issuer":{"id":5418,"kind":"organization","name":"Cabaletta Bio, Inc."},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-21T23:55:49.000Z","date":"2026-01-21","kind":"purchase","planned":false,"acquired":true,"shares":22725,"price":2.2144,"value":50322.24,"ownership":{"direct":false,"nature":"By Shawn Tomasello Consulting LLC"},"balance_after":22725,"source":{"system":"sec-edgar","filing":"0001193125-26-018324","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759138/000119312526018324/ownership.xml","form_type":"4"}},{"id":1104600,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:04:56.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2026 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2028. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan)."}],"balance_after":22500,"derivative":{"exercise_price":4.15,"expiration_date":"2035-06-16","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0000950170-25-088489","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1617239/000095017025088489/ownership.xml","form_type":"4"}},{"id":1117999,"issuer":{"id":5418,"kind":"organization","name":"Cabaletta Bio, Inc."},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-10T00:17:23.000Z","date":"2025-06-09","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 9, 2026 or (ii) the date of the next annual meeting of the Corporation's stockholders."}],"balance_after":22000,"derivative":{"exercise_price":2.37,"expiration_date":"2035-06-08","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0000950170-25-084015","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759138/000095017025084015/ownership.xml","form_type":"4"}},{"id":1142866,"issuer":{"id":5418,"kind":"organization","name":"Cabaletta Bio, Inc."},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-20T01:38:50.000Z","date":"2025-05-19","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $1.92 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date.  Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\", through which the Reporting Person must remain in service to the Issuer, commenced on the Repricing Date and ends upon the earliest of (i) the one-year anniversary of the Repricing Date, (ii) a Sale Event (as defined in the 2018 Plan and 2019 Plan, as applicable) and (iii) the termination of the Reporting Person's Service Relationship (as defined in the 2018 Plan and 2019 Plan, as applicable) due to the Reporting Person's death or disability."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 15, 2025, the Issuer's board of directors approved an option repricing (the \"Repricing\"), to be effective May 19, 2025 (the \"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Cabaletta Bio, Inc. 2018 Stock Option and Incentive Plan, as amended (the \"2018 Plan\") or the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan, as amended (the \"2019 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":22000,"derivative":{"exercise_price":1.92,"expiration_date":"2034-06-02","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0000950170-25-074823","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1759138/000095017025074823/ownership.xml","form_type":"4"}},{"id":1142865,"issuer":{"id":5418,"kind":"organization","name":"Cabaletta Bio, Inc."},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-20T01:38:50.000Z","date":"2025-05-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 15, 2025, the Issuer's board of directors approved an option repricing (the \"Repricing\"), to be effective May 19, 2025 (the \"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Cabaletta Bio, Inc. 2018 Stock Option and Incentive Plan, as amended (the \"2018 Plan\") or the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan, as amended (the \"2019 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":10.01,"expiration_date":"2034-06-02","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0000950170-25-074823","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1759138/000095017025074823/ownership.xml","form_type":"4"}},{"id":1142864,"issuer":{"id":5418,"kind":"organization","name":"Cabaletta Bio, Inc."},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-20T01:38:50.000Z","date":"2025-05-19","kind":"grant","planned":false,"acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $1.92 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date.  Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\", through which the Reporting Person must remain in service to the Issuer, commenced on the Repricing Date and ends upon the earliest of (i) the one-year anniversary of the Repricing Date, (ii) a Sale Event (as defined in the 2018 Plan and 2019 Plan, as applicable) and (iii) the termination of the Reporting Person's Service Relationship (as defined in the 2018 Plan and 2019 Plan, as applicable) due to the Reporting Person's death or disability."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 15, 2025, the Issuer's board of directors approved an option repricing (the \"Repricing\"), to be effective May 19, 2025 (the \"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Cabaletta Bio, Inc. 2018 Stock Option and Incentive Plan, as amended (the \"2018 Plan\") or the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan, as amended (the \"2019 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":44000,"derivative":{"exercise_price":1.92,"expiration_date":"2033-07-20","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0000950170-25-074823","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1759138/000095017025074823/ownership.xml","form_type":"4"}},{"id":1142863,"issuer":{"id":5418,"kind":"organization","name":"Cabaletta Bio, Inc."},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-20T01:38:50.000Z","date":"2025-05-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 15, 2025, the Issuer's board of directors approved an option repricing (the \"Repricing\"), to be effective May 19, 2025 (the \"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Cabaletta Bio, Inc. 2018 Stock Option and Incentive Plan, as amended (the \"2018 Plan\") or the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan, as amended (the \"2019 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":13.48,"expiration_date":"2033-07-20","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0000950170-25-074823","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759138/000095017025074823/ownership.xml","form_type":"4"}},{"id":1486923,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-07T20:05:07.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The shares shall vest upon the earlier to occur of (i) June 6, 2025 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":70000,"source":{"system":"sec-edgar","filing":"0000950170-24-070596","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024070596/ownership.xml","form_type":"4"}},{"id":1492466,"issuer":{"id":5418,"kind":"organization","name":"Cabaletta Bio, Inc."},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-04T23:14:53.000Z","date":"2024-06-03","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 3, 2025 or (ii) the date of the next annual meeting of the Corporation's stockholders."}],"balance_after":22000,"derivative":{"exercise_price":10.01,"expiration_date":"2034-06-02","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0000950170-24-068982","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759138/000095017024068982/ownership.xml","form_type":"4"}},{"id":1503228,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right To Buy)","published_at":"2024-05-24T00:45:00.000Z","date":"2024-05-21","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 21, 2025 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 21, 2027. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan)."}],"balance_after":22500,"derivative":{"exercise_price":25.15,"expiration_date":"2034-05-20","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0000950170-24-064259","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1617239/000095017024064259/ownership.xml","form_type":"4"}},{"id":1660763,"issuer":{"id":94655,"kind":"organization","name":"Gamida Cell Ltd.","symbol":"GMDA"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2024-02-02T16:45:46.000Z","date":"2024-01-31","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted share unit award, which shall vest on January 31, 2025, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":241977,"source":{"system":"sec-edgar","filing":"0001415889-24-002335","document":"form4-02022024_090240.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600847/000141588924002335/form4-02022024_090240.xml","form_type":"4"}},{"id":1756806,"issuer":{"id":94655,"kind":"organization","name":"Gamida Cell Ltd.","symbol":"GMDA"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2023-10-20T16:39:11.000Z","date":"2023-10-19","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option grant was approved by the Board of Directors of the Issuer on March 20, 2023, subject to shareholder approval. The Issuer's shareholders approved the grant at the annual general meeting of the shareholders on October 19, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests in equal quarterly installments over a twelve-month period, with the first such installment vesting on May 8, 2023, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":17000,"derivative":{"exercise_price":1.32,"expiration_date":"2023-10-18","underlying":"Ordinary Shares","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001209191-23-053267","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600847/000120919123053267/doc4a.xml","form_type":"4/A","original_submission_date":"2023-03-22"}},{"id":1756805,"issuer":{"id":94655,"kind":"organization","name":"Gamida Cell Ltd.","symbol":"GMDA"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2023-10-20T16:38:03.000Z","date":"2023-10-19","kind":"grant","planned":false,"acquired":true,"shares":56600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F3","text":"The option grant was approved by the Board of Directors of the Issuer on February 8, 2023, subject to shareholder approval. The Issuer's shareholders approved the grant at the annual general meeting of the shareholders on October 19, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option vests in equal quarterly installments over a twelve-month period, with the first such installment vesting on May 8, 2023, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":56600,"derivative":{"exercise_price":1.59,"expiration_date":"2033-10-18","underlying":"Ordinary Shares","underlying_shares":56600},"source":{"system":"sec-edgar","filing":"0001209191-23-053265","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1600847/000120919123053265/doc4a.xml","form_type":"4/A","original_submission_date":"2023-02-10"}},{"id":1756804,"issuer":{"id":94655,"kind":"organization","name":"Gamida Cell Ltd.","symbol":"GMDA"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-10-20T16:38:03.000Z","date":"2023-10-19","kind":"grant","planned":false,"acquired":true,"shares":28300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The restricted stock unit (\"RSU\") award was approved by the Board of Directors of the Issuer on February 8, 2023, subject to shareholder approval. The Issuer's shareholders approved the award at the annual general meeting of the shareholders on October 19, 2023."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents an RSU award, which shall vest on February 8, 2024, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":41977,"source":{"system":"sec-edgar","filing":"0001209191-23-053265","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600847/000120919123053265/doc4a.xml","form_type":"4/A","original_submission_date":"2023-02-10"}},{"id":1824185,"issuer":{"id":5418,"kind":"organization","name":"Cabaletta Bio, Inc."},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-24T12:26:09.000Z","date":"2023-07-21","kind":"grant","planned":false,"acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in twelve substantially equal quarterly installments following July 21, 2023, subject to the reporting person's continued service on each such vesting date."}],"balance_after":44000,"derivative":{"exercise_price":13.48,"expiration_date":"2033-07-20","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0000950170-23-033944","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759138/000095017023033944/ownership.xml","form_type":"4"}},{"id":1872148,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-01T16:32:06.000Z","date":"2023-06-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4177,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the \"Company\"), Adaptimmune Therapeutics plc (\"Parent\") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent (\"Merger Sub\"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the \"Merger Agreement\"), pursuant to which Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Company (each, a \"Share\") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the \"Exchange Ratio\") American Depositary Shares of Parent (\"Parent ADS\") representing six ordinary shares of Parent (\"Parent Ordinary Shares\"). Immediately prior to the Effective Time, each option to acquire Shares (each, a \"Company Option\") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Company (each, a \"Share\") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the \"Exchange Ratio\") American Depositary Shares of Parent (\"Parent ADS\") representing six ordinary shares of Parent (\"Parent Ordinary Shares\"). Immediately prior to the Effective Time, each option to acquire Shares (each, a \"Company Option\") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Company (each, a \"Share\") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the \"Exchange Ratio\") American Depositary Shares of Parent (\"Parent ADS\") representing six ordinary shares of Parent (\"Parent Ordinary Shares\"). Immediately prior to the Effective Time, each option to acquire Shares (each, a \"Company Option\") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs."}],"balance_after":0,"derivative":{"exercise_price":26.33,"underlying":"Common Stock","underlying_shares":4177},"source":{"system":"sec-edgar","filing":"0001104659-23-067078","document":"tm2317472-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000110465923067078/tm2317472-11_4seq1.xml","form_type":"4"}},{"id":1872147,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-01T16:32:06.000Z","date":"2023-06-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15191,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the \"Company\"), Adaptimmune Therapeutics plc (\"Parent\") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent (\"Merger Sub\"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the \"Merger Agreement\"), pursuant to which Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Company (each, a \"Share\") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the \"Exchange Ratio\") American Depositary Shares of Parent (\"Parent ADS\") representing six ordinary shares of Parent (\"Parent Ordinary Shares\"). Immediately prior to the Effective Time, each option to acquire Shares (each, a \"Company Option\") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Company (each, a \"Share\") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the \"Exchange Ratio\") American Depositary Shares of Parent (\"Parent ADS\") representing six ordinary shares of Parent (\"Parent Ordinary Shares\"). Immediately prior to the Effective Time, each option to acquire Shares (each, a \"Company Option\") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Company (each, a \"Share\") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the \"Exchange Ratio\") American Depositary Shares of Parent (\"Parent ADS\") representing six ordinary shares of Parent (\"Parent Ordinary Shares\"). Immediately prior to the Effective Time, each option to acquire Shares (each, a \"Company Option\") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs."}],"balance_after":0,"derivative":{"exercise_price":26.33,"underlying":"Common Stock","underlying_shares":15191},"source":{"system":"sec-edgar","filing":"0001104659-23-067078","document":"tm2317472-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000110465923067078/tm2317472-11_4seq1.xml","form_type":"4"}},{"id":1872146,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-01T16:32:06.000Z","date":"2023-06-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the \"Company\"), Adaptimmune Therapeutics plc (\"Parent\") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent (\"Merger Sub\"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the \"Merger Agreement\"), pursuant to which Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Company (each, a \"Share\") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the \"Exchange Ratio\") American Depositary Shares of Parent (\"Parent ADS\") representing six ordinary shares of Parent (\"Parent Ordinary Shares\"). Immediately prior to the Effective Time, each option to acquire Shares (each, a \"Company Option\") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Company (each, a \"Share\") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the \"Exchange Ratio\") American Depositary Shares of Parent (\"Parent ADS\") representing six ordinary shares of Parent (\"Parent Ordinary Shares\"). Immediately prior to the Effective Time, each option to acquire Shares (each, a \"Company Option\") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Company (each, a \"Share\") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the \"Exchange Ratio\") American Depositary Shares of Parent (\"Parent ADS\") representing six ordinary shares of Parent (\"Parent Ordinary Shares\"). Immediately prior to the Effective Time, each option to acquire Shares (each, a \"Company Option\") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs."}],"balance_after":0,"derivative":{"exercise_price":5.21,"underlying":"Common Stock","underlying_shares":12100},"source":{"system":"sec-edgar","filing":"0001104659-23-067078","document":"tm2317472-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000110465923067078/tm2317472-11_4seq1.xml","form_type":"4"}},{"id":1872145,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-01T16:32:06.000Z","date":"2023-06-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the \"Company\"), Adaptimmune Therapeutics plc (\"Parent\") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent (\"Merger Sub\"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the \"Merger Agreement\"), pursuant to which Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Company (each, a \"Share\") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the \"Exchange Ratio\") American Depositary Shares of Parent (\"Parent ADS\") representing six ordinary shares of Parent (\"Parent Ordinary Shares\"). Immediately prior to the Effective Time, each option to acquire Shares (each, a \"Company Option\") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Company (each, a \"Share\") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the \"Exchange Ratio\") American Depositary Shares of Parent (\"Parent ADS\") representing six ordinary shares of Parent (\"Parent Ordinary Shares\"). Immediately prior to the Effective Time, each option to acquire Shares (each, a \"Company Option\") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Company (each, a \"Share\") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the \"Exchange Ratio\") American Depositary Shares of Parent (\"Parent ADS\") representing six ordinary shares of Parent (\"Parent Ordinary Shares\"). Immediately prior to the Effective Time, each option to acquire Shares (each, a \"Company Option\") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs."}],"balance_after":0,"derivative":{"exercise_price":0.97,"underlying":"Common Stock","underlying_shares":16800},"source":{"system":"sec-edgar","filing":"0001104659-23-067078","document":"tm2317472-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000110465923067078/tm2317472-11_4seq1.xml","form_type":"4"}},{"id":1877662,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-25T23:39:14.000Z","date":"2023-05-23","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 23, 2024 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 23, 2026. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan)."}],"balance_after":22500,"derivative":{"exercise_price":17.98,"expiration_date":"2033-05-22","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001610717-23-000072","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1617239/000161071723000072/form4.xml","form_type":"4"}},{"id":1895161,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-12T21:00:30.000Z","date":"2023-05-11","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The shares shall vest upon the earlier to occur of (i) May 11, 2024 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":35000,"source":{"system":"sec-edgar","filing":"0001209191-23-029097","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919123029097/doc4.xml","form_type":"4"}},{"id":1941185,"issuer":{"id":94655,"kind":"organization","name":"Gamida Cell Ltd.","symbol":"GMDA"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2023-03-22T16:34:41.000Z","date":"2023-03-20","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in equal quarterly installments over a twelve-month period, with the first such installment vesting on May 8, 2023, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":17000,"derivative":{"exercise_price":1.32,"expiration_date":"2033-03-19","underlying":"Ordinary Shares","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001209191-23-020521","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600847/000120919123020521/doc4.xml","form_type":"4"}},{"id":2022175,"issuer":{"id":94655,"kind":"organization","name":"Gamida Cell Ltd.","symbol":"GMDA"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2023-02-10T19:30:32.000Z","date":"2023-02-08","kind":"grant","acquired":true,"shares":56600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests in equal quarterly installments over a twelve-month period, with the first such installment vesting on May 8, 2023, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":56600,"derivative":{"exercise_price":1.59,"expiration_date":"2033-02-07","underlying":"Ordinary Shares","underlying_shares":56600},"source":{"system":"sec-edgar","filing":"0001209191-23-008551","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1600847/000120919123008551/doc4.xml","form_type":"4"}},{"id":2022174,"issuer":{"id":94655,"kind":"organization","name":"Gamida Cell Ltd.","symbol":"GMDA"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-02-10T19:30:32.000Z","date":"2023-02-08","kind":"grant","acquired":true,"shares":28300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted share unit award, which shall vest on February 8, 2024, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":41977,"source":{"system":"sec-edgar","filing":"0001209191-23-008551","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600847/000120919123008551/doc4.xml","form_type":"4"}},{"id":2081779,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-19T17:10:02.000Z","date":"2022-12-15","kind":"grant","acquired":true,"shares":16800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest and become exercisable on January 1, 2024, with the remainder vesting in twenty-four (24) equal monthly installments thereafter."}],"balance_after":16800,"derivative":{"exercise_price":0.97,"expiration_date":"2032-12-14","underlying":"Common Stock","underlying_shares":16800},"source":{"system":"sec-edgar","filing":"0000899243-22-039011","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924322039011/doc4.xml","form_type":"4"}},{"id":2106348,"issuer":{"id":94655,"kind":"organization","name":"Gamida Cell Ltd.","symbol":"GMDA"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2022-11-22T16:37:31.000Z","date":"2022-11-18","kind":"grant","acquired":true,"shares":9500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests in equal quarterly installments over a twelve-month period, with the first such installment vesting on February 1, 2023, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":9500,"derivative":{"exercise_price":1.79,"expiration_date":"2032-11-17","underlying":"Ordinary Shares","underlying_shares":9500},"source":{"system":"sec-edgar","filing":"0001209191-22-058395","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1600847/000120919122058395/doc4.xml","form_type":"4"}},{"id":2106347,"issuer":{"id":94655,"kind":"organization","name":"Gamida Cell Ltd.","symbol":"GMDA"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2022-11-22T16:37:31.000Z","date":"2022-11-18","kind":"grant","acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted share unit award, which shall vest on November 1, 2023, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":13677,"source":{"system":"sec-edgar","filing":"0001209191-22-058395","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600847/000120919122058395/doc4.xml","form_type":"4"}},{"id":2143634,"issuer":{"id":94655,"kind":"organization","name":"Gamida Cell Ltd.","symbol":"GMDA"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2022-10-04T16:39:45.000Z","date":"2022-09-30","kind":"purchase","acquired":true,"shares":9677,"price":1.55,"value":14999.35,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person purchased ordinary shares of the Issuer at a price of $1.55 per share in an underwritten public offering by the Issuer, which closed on September 30, 2022."}],"balance_after":11677,"source":{"system":"sec-edgar","filing":"0001209191-22-052284","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1600847/000120919122052284/doc4.xml","form_type":"4"}},{"id":2256411,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-25T23:08:10.000Z","date":"2022-05-23","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 23, 2023 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 23, 2025. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan)."}],"balance_after":22500,"derivative":{"exercise_price":7.77,"expiration_date":"2032-05-22","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001567619-22-011723","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1617239/000156761922011723/doc1.xml","form_type":"4"}},{"id":2263864,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-19T20:20:11.000Z","date":"2022-05-17","kind":"grant","acquired":true,"shares":27500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable upon the earlier to occur of (i) May 17, 2023 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":27500,"derivative":{"exercise_price":4.6,"expiration_date":"2032-05-16","underlying":"Common Stock","underlying_shares":27500},"source":{"system":"sec-edgar","filing":"0000899243-22-018805","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322018805/doc4.xml","form_type":"4"}},{"id":2312991,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-31T21:20:13.000Z","date":"2022-03-29","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in twelve (12) equal quarterly installments, with the first installment vesting on June 29, 2022."}],"balance_after":45000,"derivative":{"exercise_price":7.88,"expiration_date":"2032-03-29","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0000899243-22-012968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322012968/doc4.xml","form_type":"4"}},{"id":2477339,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-10T16:35:27.000Z","date":"2021-12-09","kind":"grant","acquired":true,"shares":12100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in twenty-four (24) equal monthly installments thereafter."}],"balance_after":12100,"derivative":{"exercise_price":5.21,"expiration_date":"2031-12-08","underlying":"Common Stock","underlying_shares":12100},"source":{"system":"sec-edgar","filing":"0001209191-21-069058","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000120919121069058/doc4.xml","form_type":"4"}},{"id":2675679,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-09T17:43:13.000Z","date":"2021-06-07","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option will vest in equal quarterly installments over a period of one year."}],"balance_after":10000,"derivative":{"exercise_price":17.98,"expiration_date":"2031-06-06","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-039133","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919121039133/doc4.xml","form_type":"4"}},{"id":2704821,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-20T00:31:39.000Z","date":"2021-05-17","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 17, 2022 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 17, 2024. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan)."}],"balance_after":22500,"derivative":{"exercise_price":26.89,"expiration_date":"2031-05-16","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001567619-21-010746","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1617239/000156761921010746/doc1.xml","form_type":"4"}},{"id":2879270,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-04T16:08:22.000Z","date":"2021-02-03","kind":"grant","acquired":true,"shares":4177,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest and become exercisable on February 3, 2022, with the remainder vesting in twenty-four (24) equal monthly installments thereafter"}],"balance_after":4177,"derivative":{"exercise_price":26.33,"expiration_date":"2031-02-02","underlying":"Common Stock","underlying_shares":4177},"source":{"system":"sec-edgar","filing":"0001209191-21-007718","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000120919121007718/doc4.xml","form_type":"4"}},{"id":2879269,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-04T16:08:22.000Z","date":"2021-02-03","kind":"grant","acquired":true,"shares":15191,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest and become exercisable on February 3, 2022, with the remainder vesting in twenty-four (24) equal monthly installments thereafter"}],"balance_after":15191,"derivative":{"exercise_price":26.33,"expiration_date":"2031-02-02","underlying":"Common Stock","underlying_shares":15191},"source":{"system":"sec-edgar","filing":"0001209191-21-007718","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000120919121007718/doc4.xml","form_type":"4"}},{"id":3021554,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-09-28T17:29:51.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":10240,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the \"Issuer\"), Sanofi (\"Sanofi\") and Kortex Acquisition Corp. (\"Purchaser\") (the \"Merger Agreement\"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the \"Issuer\"), Sanofi (\"Sanofi\") and Kortex Acquisition Corp. (\"Purchaser\") (the \"Merger Agreement\"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the \"Issuer\"), Sanofi (\"Sanofi\") and Kortex Acquisition Corp. (\"Purchaser\") (the \"Merger Agreement\"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":62.66,"expiration_date":"2030-06-03","underlying":"Common Stock","underlying_shares":10240},"source":{"system":"sec-edgar","filing":"0001209191-20-052237","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919120052237/doc4.xml","form_type":"4"}},{"id":3021553,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-09-28T17:29:51.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":20475,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the \"Issuer\"), Sanofi (\"Sanofi\") and Kortex Acquisition Corp. (\"Purchaser\") (the \"Merger Agreement\"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the \"Issuer\"), Sanofi (\"Sanofi\") and Kortex Acquisition Corp. (\"Purchaser\") (the \"Merger Agreement\"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the \"Issuer\"), Sanofi (\"Sanofi\") and Kortex Acquisition Corp. (\"Purchaser\") (the \"Merger Agreement\"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":36.79,"expiration_date":"2029-08-28","underlying":"Common Stock","underlying_shares":20475},"source":{"system":"sec-edgar","filing":"0001209191-20-052237","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919120052237/doc4.xml","form_type":"4"}},{"id":3114838,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-10T22:43:04.000Z","date":"2020-06-08","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option will vest in equal quarterly installments over a period of one year."}],"balance_after":10000,"derivative":{"exercise_price":28.24,"expiration_date":"2030-06-07","underlying":"Ordinary Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-20-035684","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919120035684/doc4.xml","form_type":"4"}},{"id":3118185,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-06-08T20:12:58.000Z","date":"2020-06-04","kind":"grant","acquired":true,"shares":10240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":10240,"derivative":{"exercise_price":62.66,"expiration_date":"2030-06-03","underlying":"Common Stock","underlying_shares":10240},"source":{"system":"sec-edgar","filing":"0001209191-20-035144","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919120035144/doc4.xml","form_type":"4"}},{"id":3138318,"issuer":{"id":5808,"kind":"organization","name":"ABEONA THERAPEUTICS INC."},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-05-22T22:21:49.000Z","date":"2020-05-20","kind":"grant","acquired":true,"shares":43035,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the stock options will vest on November 20, 2020."}],"balance_after":43035,"derivative":{"exercise_price":3.2,"expiration_date":"2030-05-20","underlying":"Common Stock","underlying_shares":43035},"source":{"system":"sec-edgar","filing":"0001493152-20-009770","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/318306/000149315220009770/ownership.xml","form_type":"4"}},{"id":3138317,"issuer":{"id":5808,"kind":"organization","name":"ABEONA THERAPEUTICS INC."},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-22T22:21:49.000Z","date":"2020-05-20","kind":"grant","acquired":true,"shares":35938,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"All of the restricted stock will vest on November 20, 2020."}],"balance_after":35938,"source":{"system":"sec-edgar","filing":"0001493152-20-009770","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318306/000149315220009770/ownership.xml","form_type":"4"}},{"id":3281574,"issuer":{"id":151818,"kind":"organization","name":"Diplomat Pharmacy, Inc.","symbol":"DPLO"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-10T16:18:00.000Z","date":"2020-02-10","kind":"disposition_to_issuer","acquired":false,"shares":33259,"price":4,"value":133036.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated December 9, 2019 (the \"Merger Agreement\"), by and among UnitedHealth Group Incorporated, a Delaware corporation (\"Parent\"), Purchaser, a Michigan corporation and a wholly owned subsidiary of Parent and Diplomat Pharmacy, Inc., a Michigan corporation (the \"Issuer\"), each outstanding restricted stock award held by reporting person was disposed of pursuant to the closing on February 10, 2020 of the merger of Purchaser with and into the Issuer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-20-013515","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1610092/000110465920013515/a4.xml","form_type":"4"}},{"id":3281573,"issuer":{"id":151818,"kind":"organization","name":"Diplomat Pharmacy, Inc.","symbol":"DPLO"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-10T16:18:00.000Z","date":"2020-02-10","kind":"other","acquired":false,"shares":11278,"price":4,"value":45112.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares tendered to the Denali Merger Sub, Inc. (\"Purchaser\") in connection with the closing on February 10, 2020 of a cash tender offer by Purchaser to acquire common stock of Issuer in exchange for $4.00 per share in cash, subject to any required withholding of taxes, without interest."}],"balance_after":33259,"source":{"system":"sec-edgar","filing":"0001104659-20-013515","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610092/000110465920013515/a4.xml","form_type":"4"}},{"id":3397136,"issuer":{"id":151818,"kind":"organization","name":"Diplomat Pharmacy, Inc.","symbol":"DPLO"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-10-04T16:48:03.000Z","date":"2019-10-02","kind":"sale","acquired":false,"shares":859,"price":4.84,"value":4157.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 represent shares sold automatically to cover the tax liability incurred incident to the vesting of previously granted restricted stock."},{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 represent shares sold automatically to cover the tax liability incurred incident to the vesting of previously granted restricted stock."}],"balance_after":44537,"source":{"system":"sec-edgar","filing":"0001596771-19-000120","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610092/000159677119000120/primary_doc.xml","form_type":"4"}},{"id":3422918,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2019-09-04T16:34:55.000Z","date":"2019-08-29","kind":"grant","acquired":true,"shares":20475,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over a three year period, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Due to administrative error, a separate option award was erroneously included on the original Form 4 filed on August 30, 2019. That original Form 4 is hereby amended in its entirety."}],"balance_after":20475,"derivative":{"exercise_price":36.79,"expiration_date":"2029-08-28","underlying":"Common Stock","underlying_shares":20475},"source":{"system":"sec-edgar","filing":"0001209191-19-048210","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919119048210/doc4a.xml","form_type":"4/A","original_submission_date":"2019-08-30"}},{"id":3425746,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2019-08-30T16:49:47.000Z","date":"2019-08-29","kind":"grant","acquired":true,"shares":10240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":10240,"derivative":{"exercise_price":36.79,"expiration_date":"2029-08-28","underlying":"Common Stock","underlying_shares":10240},"source":{"system":"sec-edgar","filing":"0001209191-19-047836","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919119047836/doc4.xml","form_type":"4"}},{"id":3425745,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2019-08-30T16:49:47.000Z","date":"2019-08-29","kind":"grant","acquired":true,"shares":20475,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over a three year period, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":20475,"derivative":{"exercise_price":36.79,"expiration_date":"2029-08-28","underlying":"Common Stock","underlying_shares":20475},"source":{"system":"sec-edgar","filing":"0001209191-19-047836","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919119047836/doc4.xml","form_type":"4"}},{"id":3500643,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-05T21:02:36.000Z","date":"2019-06-03","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option will vest in equal quarterly installments over a period of two years."}],"balance_after":10000,"derivative":{"exercise_price":34.83,"expiration_date":"2029-06-02","underlying":"Ordinary Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-19-034793","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919119034793/doc4.xml","form_type":"4"}},{"id":3499944,"issuer":{"id":151818,"kind":"organization","name":"Diplomat Pharmacy, Inc.","symbol":"DPLO"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-05T16:41:38.000Z","date":"2019-06-04","kind":"sale","acquired":false,"shares":1274,"price":4.8546,"value":6184.7604,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 represent shares sold to cover the tax liability incurred incident to the vesting of previously granted restricted stock."},{"field":"shares","element":"transactionShares","label":"F2","text":"The sales reported in this Form 4 represent shares sold to cover the tax liability incurred incident to the vesting of previously granted restricted stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price represents the weighted average price of the multiple transactions reported on this line. Upon request by the SEC staff, the issuer or any securityholder of the issuer, the reporting person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":45396,"source":{"system":"sec-edgar","filing":"0001596771-19-000057","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1610092/000159677119000057/primary_doc.xml","form_type":"4"}},{"id":3499943,"issuer":{"id":151818,"kind":"organization","name":"Diplomat Pharmacy, Inc.","symbol":"DPLO"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-05T16:41:38.000Z","date":"2019-06-03","kind":"grant","acquired":true,"shares":33259,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of restricted stock were granted in connection with the Issuer's non-employee director compensation program."}],"balance_after":46670,"source":{"system":"sec-edgar","filing":"0001596771-19-000057","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610092/000159677119000057/primary_doc.xml","form_type":"4"}},{"id":3797807,"issuer":{"id":151818,"kind":"organization","name":"Diplomat Pharmacy, Inc.","symbol":"DPLO"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-10-03T16:33:36.000Z","date":"2018-10-01","kind":"grant","acquired":true,"shares":2275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of restricted stock were granted in connection with the Issuer's revised non-employee director compensation program, effective October 1, 2018."}],"balance_after":13411,"source":{"system":"sec-edgar","filing":"0001596771-18-000096","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610092/000159677118000096/primary_doc.xml","form_type":"4"}},{"id":3904383,"issuer":{"id":151818,"kind":"organization","name":"Diplomat Pharmacy, Inc.","symbol":"DPLO"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-05T17:14:35.000Z","date":"2018-06-05","kind":"sale","acquired":false,"shares":1680,"price":24.2654,"value":40765.872,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 represent shares sold to cover the tax liability incurred incident to the vesting of previously granted restricted stock."},{"field":"shares","element":"transactionShares","label":"F2","text":"The sales reported in this Form 4 represent shares sold to cover the tax liability incurred incident to the vesting of previously granted restricted stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price represents the weighted average price of the multiple transactions reported on this line. The shares were sold at prices ranging from $24.2101 to $24.46. Upon request by the SEC staff, the Issuer or any securityholder of the Issuer, the reporting person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":11136,"source":{"system":"sec-edgar","filing":"0001596771-18-000072","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1610092/000159677118000072/primary_doc.xml","form_type":"4"}},{"id":3904382,"issuer":{"id":151818,"kind":"organization","name":"Diplomat Pharmacy, Inc.","symbol":"DPLO"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-05T17:14:35.000Z","date":"2018-06-01","kind":"grant","acquired":true,"shares":3654,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of restricted stock were granted in connection with the Issuer's non-employee director compensation program."}],"balance_after":12816,"source":{"system":"sec-edgar","filing":"0001596771-18-000072","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610092/000159677118000072/primary_doc.xml","form_type":"4"}},{"id":4190763,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-10-05T20:16:38.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":38500,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a \"Company Option\") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into\nan option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This option provides for 25% vesting on December 22, 2017, and vesting thereafter in 36 equal monthly installments."}],"balance_after":0,"derivative":{"exercise_price":46.09,"expiration_date":"2026-12-21","underlying":"Common Stock","underlying_shares":38500},"source":{"system":"sec-edgar","filing":"0001209191-17-056222","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117056222/doc4.xml","form_type":"4"}},{"id":4190762,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-10-05T20:16:38.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":67000,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a \"Company Option\") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into\nan option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option provided for 25% vesting on December 17, 2016, and vesting thereafter in 36 equal monthly installments."}],"balance_after":0,"derivative":{"exercise_price":63.87,"expiration_date":"2025-12-16","underlying":"Common Stock","underlying_shares":67000},"source":{"system":"sec-edgar","filing":"0001209191-17-056222","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117056222/doc4.xml","form_type":"4"}},{"id":4190761,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-10-05T20:16:38.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":93000,"price":116.13,"value":10800090.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to $180.00, less the exercise price of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option provided for 25% vesting on December 17, 2016, and vesting thereafter in 36 equal monthly installments."}],"balance_after":0,"derivative":{"exercise_price":63.87,"expiration_date":"2025-12-16","underlying":"Common Stock","underlying_shares":93000},"source":{"system":"sec-edgar","filing":"0001209191-17-056222","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117056222/doc4.xml","form_type":"4"}},{"id":4190760,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2017-10-05T20:16:38.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":39933,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of Company common stock underlying restricted stock units with respect to Company common stock, including all time-vesting and all performance-vesting restricted stock units (each a \"Company Restricted Stock Unit\"), held by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each Company Restricted Stock Unit was assumed and converted into a restricted stock unit denominated in shares of Parent common stock, on the same terms and conditions as were then applicable under such Company Restricted Stock Unit (including applicable performance vesting conditions), and relating to a number of shares of Parent common stock equal to the product of (i) the total number of shares of Company common stock subject to such Company Restricted Stock Unit multiplied by (ii) the quotient of (A) $180.00 divided by (B) the volume-weighted average closing sale price of a share of Parent common stock for the fifteen full consecutive trading days ending on and including September 28, 2017 ($83.12) (such quotient, the \"Equity Award Conversion Ratio\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each Company Restricted Stock Unit was assumed and converted into a restricted stock unit denominated in shares of Parent common stock, on the same terms and conditions as were then applicable under such Company Restricted Stock Unit (including applicable performance vesting conditions), and relating to a number of shares of Parent common stock equal to the product of (i) the total number of shares of Company common stock subject to such Company Restricted Stock Unit multiplied by (ii) the quotient of (A) $180.00 divided by (B) the volume-weighted average closing sale price of a share of Parent common stock for the fifteen full consecutive trading days ending on and including September 28, 2017 ($83.12) (such quotient, the \"Equity Award Conversion Ratio\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-17-056222","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117056222/doc4.xml","form_type":"4"}},{"id":4190759,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2017-10-05T20:16:38.000Z","date":"2017-10-03","kind":"other","acquired":false,"shares":16135,"price":180,"value":2904300.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Notes 3 and 4 below, was validly tendered for $180 per share in cash, without interest and subject to any required withholding of taxes."}],"balance_after":39933,"source":{"system":"sec-edgar","filing":"0001209191-17-056222","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117056222/doc4.xml","form_type":"4"}},{"id":4190758,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2017-10-05T20:16:38.000Z","date":"2017-09-25","kind":"gift","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":56068,"source":{"system":"sec-edgar","filing":"0001209191-17-056222","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117056222/doc4.xml","form_type":"4"}},{"id":4200677,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2017-09-27T21:44:20.000Z","date":"2017-09-25","kind":"sale","acquired":false,"shares":4203,"price":179.6639,"value":755127.3717,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The shares were sold to cover the tax obligation that occurred upon the vesting of RSU's."}],"balance_after":61068,"source":{"system":"sec-edgar","filing":"0001209191-17-054200","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117054200/doc4.xml","form_type":"4"}},{"id":4200676,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2017-09-27T21:44:20.000Z","date":"2017-09-25","kind":"grant","acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 536 shares acquired under the 2014 Employee Stock Purchase Plan on February 17, 2017."}],"balance_after":65271,"source":{"system":"sec-edgar","filing":"0001209191-17-054200","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117054200/doc4.xml","form_type":"4"}},{"id":4292239,"issuer":{"id":151818,"kind":"organization","name":"Diplomat Pharmacy, Inc.","symbol":"DPLO"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-06-05T16:29:46.000Z","date":"2017-06-01","kind":"grant","acquired":true,"shares":4722,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of restricted stock were granted in connection with the Issuer's non-employee director compensation program."}],"balance_after":9162,"source":{"system":"sec-edgar","filing":"0001596771-17-000046","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610092/000159677117000046/primary_doc.xml","form_type":"4"}},{"id":4511748,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-12-27T17:37:10.000Z","date":"2016-12-22","kind":"grant","acquired":true,"shares":38500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the stock option vest and become exercisable on the first anniversary of the grant date, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter."}],"balance_after":38500,"derivative":{"exercise_price":46.09,"expiration_date":"2026-12-22","underlying":"Common Stock","underlying_shares":38500},"source":{"system":"sec-edgar","filing":"0001209191-16-156838","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919116156838/doc4.xml","form_type":"4"}},{"id":4511747,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2016-12-27T17:37:10.000Z","date":"2016-12-22","kind":"grant","acquired":true,"shares":10600,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":60235,"source":{"system":"sec-edgar","filing":"0001209191-16-156838","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919116156838/doc4.xml","form_type":"4"}},{"id":4513032,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":36691,"kind":"person","name":"Tomasello Shawn","position":1,"cik":"0001617239","reported_name":"Tomasello Shawn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2016-12-22T16:52:09.000Z","date":"2016-12-20","kind":"sale","acquired":false,"shares":4901,"price":50.86,"value":249264.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold to cover the tax obligation that occurred upon the vesting of an RSU."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 536 shares acquired under the 2014 Employee Stock Purchase Plan on August 19, 2016."}],"balance_after":49635,"source":{"system":"sec-edgar","filing":"0001209191-16-156550","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919116156550/doc4.xml","form_type":"4"}}]}